

TAIWAN TRANSCATHETER THERAPEUTICS (TTT) 2026

10 - 11 January 2026 | NTUH International Convention Center, Taiwan

Introduction

OrbusNeich was prominently represented at the TTT 2026 Congress, held on January 10-11, 2026, at the NTUH International Convention Center in Taipei. Organized by the Taiwan Society of Cardiovascular Interventions (TSCI), aiming to promote the exchange of the latest clinical experience, technology, and research results in the field of interventional cardiology.

The two-day conference showcased advances in interventional cardiology, bringing together hundreds of local and international experts through keynote sessions and case competitions to promote clinical exchange and innovation.



Live Case Highlights

Patient History



A patient with progressive exertional dyspnea for six months, history of complex triple-vessel disease (Syntax 39.5) with prior LM-LAD and LCx-OM1 DES PCI for NSTEMI, and risk factors of type II diabetes and hyperlipidemia.

Lesion Crossing & Procedure Details

Lesion preparation involved using a guiding extension for extra support, navigating a challenging proximal cap with a microcatheter, successfully re-entering the distal true lumen, and exchanging to a Sion Blue wire for safe balloon and device delivery.

Vessel Preparation & Stenting

Vessel preparation involved sequential pre-dilatation with Sapphire® 3 and NC balloons, IVUS-confirmed severe calcification, followed by deployment of COMBO® Plus stents (3.5–4.0 mm) and high-pressure post-dilatation up to 5.0 mm for optimal stent apposition.



Result

- Micro-balloons: CTO Balloon (e.g., Sapphire® 3 0.85 mm) help cross tough segments.
- IVUS guidance: Confirms intraplaque wiring and ensures proper stent expansion.
- COMBO® Plus stent has good scaffold and is the only stent with pro-healing, helps in accelerating vessel healing even in complex calcified CTO cases.

Key Takeaways

- Successful recanalization of the RCA CTO with TIMI 3 flow.
- Optimal stent expansion and apposition confirmed by IVUS, despite the heavy calcium burden.
- The patient's exertional dyspnea improved significantly following the restoration of right coronary blood flow.

TTT 2026 served as a key platform integrating clinical practice, education, technology, and international exchange, delivering high-impact practical knowledge through live demonstrations while fostering innovation and collaboration in interventional cardiology.

In the end, TTT 2026 was a successful and memorable event for OrbusNeich with the collaborative efforts and arrangements made by OrbusNeich sales and marketing teams.